When this agonist was combined with PD-1 blockade, it yielded greater CD8+ IFN-γ positive T-cells than PD-1 blockade alone and synergistically reduced tumour growth in vivo in lung cancer murine models [269]. The gene discussed is CD8A; the disease is lung cancer.